TITLE

Systemic effects of inhaled corticosteroids are milder in asthmatic patients than in normal subjects

AUTHOR(S)
Fabbri, L.; Melara, R.
PUB. DATE
March 2001
SOURCE
Thorax;Mar2001, Vol. 56 Issue 3, p165
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Inhaled glucocorticosteroids are the first line anti-inflammatory agents for the long term treatment of asthma. They are also frequently prescribed in chronic obstructive pulmonary disease (COPD), even if their efficacy in this condition is still controversial. The inhalatory mode of administration maximizes the delivery to the airways and minimizes the systemic delivery of gIucocorticosteroids increasing the therapeutic ratio. However, long term treatment of asthma and COPD with inhaled corticosteroids is associated with a significant risk of dose related systemic adverse events.
ACCESSION #
12915602

 

Related Articles

  • Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Feldstein, Adrianne; Elmer, Patricia; Nichols, Gregory; Herson, Michael // Osteoporosis International;Dec2005, Vol. 16 Issue 12, p2168 

    Patients suffering from chronic inflammatory conditions often take glucocorticoid medications over long periods of time. More than a million patients in the United States receive these agents each year. One of the most serious side effects of this treatment is glucocorticoid-induced osteoporosis...

  • Oral Glucocorticoid-Induced Fall in Cortical Bone Volume and Density in Postmenopausal Asthmatic Patients. Tsugeno, H.; Goto, B.; Fujita, T.; Okamoto, M.; Mifune, T.; Mitsunobu, F.; Ashida, K.; Hosaki, Y.; Tsuji, T.; Tanizaki, Y. // Osteoporosis International;May2001, Vol. 12 Issue 4, p266 

    : Despite a deepening understanding of the influence of glucocorticoids (GC) on trabecular bone, little is known about GC-induced cortical bone loss. To elucidate the mechanism of GC-induced loss of cortical bone strength with particular reference to cortical bone loss, changes in cortical...

  • BMI and oral glucocorticoids as predictors of prognosis in COPD patients on long-term oxygen therapy. Ringbaek, T. J.; Viskum, K.; Lange, P. // Chronic Respiratory Disease;2004, Vol. 1 Issue 2, p71 

    Aims: The objectives of the study were to determine whether body mass index (BMI), and oral corticosteroid use predict survival and hospitalization in hypoxaemic chronic obstructive pulmonary disease (COPD) patients. Methods: The study was a prospective cohort study with analysis of a nationwide...

  • Budesonide Inhalation Suspension for the Treatment of Asthma in Infants and Children. Berger, William E. // Drugs;2005, Vol. 65 Issue 14, p1973 

    On the basis of the well recognised role of inflammation in the pathogenesis of asthma, anti-inflammatory therapy, in the form of inhaled corticosteroids, has become the mainstay of treatment in patients with persistent asthma. Budesonide inhalation suspension (BIS) is a nonhalogenated...

  • BTS/SIGN asthma advice updated.  // GP: General Practitioner;7/24/2009, p6 

    The article reports on the revisions made for the British Thoracic Society/Scottish Intercollegiate Guidelines Network on the management of asthma in Great Britain in 2009. The revised guideline states that inhaled corticosteroids might be linked with adverse effects, such as lessened bone...

  • Aspirin sparks asthma attacks.  // Consumer Reports on Health;Jun2004, Vol. 16 Issue 6, p7 

    Reveals that aspirin and related pain relievers can trigger asthma attacks in one out of five adults with the disease. Possibility that doctors did not know the extent of the prevalence of the asthma attacks; Identification of drugs that nearly all the aspirin-sensitive people reacted to;...

  • Doubling Steroids Does Not Stop Asthma Exacerbations. Walling, Anne D. // American Family Physician;9/15/2004, Vol. 70 Issue 6, p1161 

    Discusses the study "Doubling the Dose of Inhaled Corticosteroid to Prevent Asthma Exacerbations: Randomised Controlled Trial," by T. W. Harrison et al., published in the January 24, 2004 issue of the journal "The Lancet." Study subjects; Treatments given; Intepretation of the research findings.

  • Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Czock, David; Keller, Frieder; Franz Maximilian Rasche, Frieder; Häussler, Ulla; Rasche, Franz Maximilian; Häussler, Ulla // Clinical Pharmacokinetics;2005, Vol. 44 Issue 1, p61 

    Glucocorticoids have pleiotropic effects that are used to treat diverse diseases such as asthma, rheumatoid arthritis, systemic lupus erythematosus and acute kidney transplant rejection. The most commonly used systemic glucocorticoids are hydrocortisone, prednisolone, methylprednisolone and...

  • The Role of Growth Retardation in Lasting Effects of Neonatal Dexamethasone Treatment on Hippocampal Synaptic Function. Yu-Chen Wang; Chiung-Chun Huang; Kuei-Sen Hsu // PLoS ONE;2010, Vol. 5 Issue 9, p1 

    Background: Dexamethasone (DEX), a synthetic glucocorticoid, is commonly used to prevent or lessen the morbidity of chronic lung disease in preterm infants. However, evidence is now increasing that this clinical practice negatively affects somatic growth and may result in long-lasting...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics